Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

Research and Innovation Action · Running

FALCO Fighting Addictions, improving Lives: COmprehensive drug rehabilitation with music

Coordinator
Norce Research AS, Norway
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€9.0m
Total cost
—
Partners
19 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101155881

What the project is doing

In the project's own words, from its summary on CORDIS.

Objectives and ambition: Substance use disorder (SUD) is associated with a high global burden of disease, with 5.4% of all disability-adjusted life years lost due to alcohol and illicit drugs. Highly prevalent multimorbidity includes polysubstance use, mental health conditions, and other non-communicable and infectious diseases. Where traditional treatments are insufficient alone, music therapy (MT) is highly engaging and improves motivation and craving, but its long-term effects are unknown.

Methodology: In a diverse group of people with SUD across a wide range of age, gender, socioeconomic, and cultural background, a parallel 3-arm assessor-blinded pragmatic multinational randomised clinical trial with embedded exploratory trials and mechanistic studies will determine long-term effects of active music groups (AMG) and music listening groups (MLG) versus treatment as usual (TAU) on addiction severity (primary: 1 year), recovery, and other health and socioeconomic outcomes.

Embedded trials will examine short-term effects of individual components of TAU combined with AMG or MLG to determine the best combinations of interventions. Experimental studies will examine mechanisms using neuropsychological tests and brain imaging. With 600 participants in 7 countries randomised, the trial has 80% power on the primary outcome. Patient representatives, HTA bodies, and interventionists have been involved from conception and will ensure feasibility and applicability across Europe.

Impact: FALCO will reduce disease burden through innovative, effective, and affordable treatment and will strengthen research and innovation expertise. Recommendations from FALCO will inform intervention delivery across Europe and beyond, leading to increased safety, effectiveness and cost-effectiveness, and improved quality of life for people with SUD. Stakeholders will be involved in communicating findings in all European countries and regions and ensuring that findings are effectively implemented.

Topics

Who is involved

OrganisationCityCountryRole
Norce Research ASBergenNorwayCoordinator
Hta Austria - Austrian Institute for Health Technology Assessment GmbHWienAustriaParticipant
Stiftung Anton Proksch - Institut WienWienAustriaParticipant
Universitat Fur Musik Und Darstellende Kunst WienWienAustriaParticipant
Universitat WienWienAustriaParticipant
Universitat ZurichZurichSwitzerlandAssociatedpartner
Fundacio Institut D'investigacio Biomedica De BellvitgeL'Hospitalet De LlobregatSpainParticipant
Fundacio Institut D'investigacio Biomedica De Girona Doctor Josep TruetaGironaSpainParticipant
Fundació Sanitària d'IgualadaIgualadaSpainParticipant
Institucio Catalana De Recerca I Estudis Avancats Fundacio PrivadaBarcelonaSpainThird party
Universitat De GironaGironaSpainParticipant
Bar Ilan UniversityRamat GanIsraelParticipant
Herzog CollegeJerusalemIsraelParticipant
Universita Degli Studi Di PaviaPaviaItalyParticipant
Helse Stavanger HfStavangerNorwayParticipant
Sykehuset Innlandet HfBrumunddalNorwayParticipant
Universitetet I BergenBergenNorwayParticipant
Uniwersytet GdanskiGdanskPolandParticipant
Wojewodzki Osrodek Terapii Uzaleznien W GdanskuGdanskPolandThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI